tegafur has been researched along with Esophageal Squamous Cell Carcinoma in 11 studies
Esophageal Squamous Cell Carcinoma: A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In advanced esophageal squamous cell carcinoma (ESCC), paclitaxel plus cisplatin are considered as active and tolerable." | 7.85 | A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma. ( Jin, SL; Liu, YY; Luo, SX; Tang, H; Wang, HY; Yang, SJ; Yao, SN; Yao, ZH; Zhao, Y; Zhou, WP, 2017) |
| "Apatinib has shown promising outcomes in treatment with various solid tumors." | 6.94 | Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma. ( Lei, J; Song, X; Wang, Y; Yu, J; Zhang, C; Zhang, N; Zhang, S; Zhao, J, 2020) |
| "Although standard chemotherapy for esophageal cancer patients is fluorouracil and cisplatin, the prognosis is still unsatisfactory." | 6.82 | Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. ( Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K, 2016) |
| " We performed this retrospective study to evaluate the efficacy and safety of apatinib combined with S-1/capecitabine as the oral maintenance therapy for these patients." | 5.62 | Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy. ( Bai, K; Chen, B; Chi, D; Guo, S; Hu, Y; Li, Q; Ma, H; Zhu, Y, 2021) |
| "In Japan, esophagectomy after two courses of 5-fluorouracil plus cisplatin is regarded a standard strategy for treating stage II or III esophageal squamous cell carcinoma (ESCC)." | 5.34 | An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus. ( Hattori, N; Hayashi, M; Iwata, N; Kanda, M; Kodera, Y; Koike, M; Nakayama, G; Omae, K; Shimizu, D; Tanaka, C; Yamada, S, 2020) |
| "Platinum plus 5-fluorouracil (FP) is a first-line regimen of palliative chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma (RM-ESCC)." | 3.91 | S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma. ( Boku, N; Hirano, H; Honma, Y; Ito, T; Iwasa, S; Kato, K; Okita, N; Shoji, H; Takashima, A, 2019) |
| "In advanced esophageal squamous cell carcinoma (ESCC), paclitaxel plus cisplatin are considered as active and tolerable." | 3.85 | A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma. ( Jin, SL; Liu, YY; Luo, SX; Tang, H; Wang, HY; Yang, SJ; Yao, SN; Yao, ZH; Zhao, Y; Zhou, WP, 2017) |
| "Apatinib has shown promising outcomes in treatment with various solid tumors." | 2.94 | Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma. ( Lei, J; Song, X; Wang, Y; Yu, J; Zhang, C; Zhang, N; Zhang, S; Zhao, J, 2020) |
| "The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established." | 2.90 | Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial. ( Ba, Y; Bai, Y; Cheng, Y; Fan, Q; Feng, J; Hu, C; Huang, J; Li, J; Liu, Y; Lu, P; Ma, C; Wang, X; Wen, L; Wu, L; Xu, B; Yuan, X; Zhang, S, 2019) |
| "Although standard chemotherapy for esophageal cancer patients is fluorouracil and cisplatin, the prognosis is still unsatisfactory." | 2.82 | Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. ( Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K, 2016) |
| " We performed this retrospective study to evaluate the efficacy and safety of apatinib combined with S-1/capecitabine as the oral maintenance therapy for these patients." | 1.62 | Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy. ( Bai, K; Chen, B; Chi, D; Guo, S; Hu, Y; Li, Q; Ma, H; Zhu, Y, 2021) |
| "It may be useful for esophageal squamous cell carcinoma (ESCC); however, there are insufficient data." | 1.39 | S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma. ( Akutsu, Y; Hanaoka, T; Hoshino, I; Kono, T; Matsubara, H; Narushima, K; Qin, W; Semba, Y; Tochigi, T; Uesato, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, J | 1 |
| Lei, J | 1 |
| Yu, J | 1 |
| Zhang, C | 1 |
| Song, X | 1 |
| Zhang, N | 1 |
| Wang, Y | 1 |
| Zhang, S | 2 |
| Kanda, M | 1 |
| Koike, M | 1 |
| Iwata, N | 1 |
| Shimizu, D | 1 |
| Tanaka, C | 1 |
| Hattori, N | 1 |
| Hayashi, M | 1 |
| Yamada, S | 1 |
| Omae, K | 1 |
| Nakayama, G | 1 |
| Kodera, Y | 1 |
| Chi, D | 1 |
| Chen, B | 1 |
| Guo, S | 1 |
| Bai, K | 1 |
| Ma, H | 1 |
| Hu, Y | 1 |
| Li, Q | 1 |
| Zhu, Y | 1 |
| Ojima, T | 1 |
| Nakamura, M | 1 |
| Nakamori, M | 1 |
| Katsuda, M | 1 |
| Hayata, K | 1 |
| Maruoka, S | 1 |
| Shimokawa, T | 1 |
| Yamaue, H | 1 |
| Sun, S | 1 |
| Yu, H | 1 |
| Wang, H | 1 |
| Zhang, H | 1 |
| Wu, X | 1 |
| Wang, J | 1 |
| Chang, J | 1 |
| Huang, J | 2 |
| Xu, B | 1 |
| Liu, Y | 1 |
| Lu, P | 1 |
| Ba, Y | 1 |
| Wu, L | 1 |
| Bai, Y | 1 |
| Feng, J | 1 |
| Cheng, Y | 1 |
| Li, J | 1 |
| Wen, L | 1 |
| Yuan, X | 1 |
| Ma, C | 1 |
| Hu, C | 1 |
| Fan, Q | 1 |
| Wang, X | 1 |
| Ito, T | 1 |
| Honma, Y | 1 |
| Hirano, H | 1 |
| Shoji, H | 1 |
| Okita, N | 1 |
| Iwasa, S | 1 |
| Takashima, A | 1 |
| Kato, K | 1 |
| Boku, N | 1 |
| Akutsu, Y | 1 |
| Kono, T | 1 |
| Uesato, M | 1 |
| Hoshino, I | 1 |
| Narushima, K | 1 |
| Hanaoka, T | 1 |
| Tochigi, T | 1 |
| Semba, Y | 1 |
| Qin, W | 1 |
| Matsubara, H | 1 |
| Tanaka, Y | 1 |
| Yoshida, K | 1 |
| Tanahashi, T | 1 |
| Okumura, N | 1 |
| Matsuhashi, N | 1 |
| Yamaguchi, K | 1 |
| Kano, K | 1 |
| Sato, T | 1 |
| Maezawa, Y | 1 |
| Segami, K | 1 |
| Nakajima, T | 1 |
| Ikeda, K | 1 |
| Hayashi, T | 1 |
| Yamada, T | 1 |
| Yamamoto, N | 1 |
| Ohshima, T | 1 |
| Yukawa, N | 1 |
| Rino, Y | 1 |
| Masuda, M | 1 |
| Ogata, T | 1 |
| Cho, H | 1 |
| Yoshikawa, T | 1 |
| Wang, HY | 1 |
| Yao, ZH | 1 |
| Tang, H | 1 |
| Zhao, Y | 1 |
| Jin, SL | 1 |
| Zhou, WP | 1 |
| Yao, SN | 1 |
| Yang, SJ | 1 |
| Liu, YY | 1 |
| Luo, SX | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma (ESWN 01 Trial): a Phase 3, Prospective,Multicenter, Randomised Study[NCT02319187] | Phase 3 | 240 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for tegafur and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Esop | 2020 |
An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Comb | 2020 |
Phase I/II Trial of Chemotherapy with Docetaxel, Cisplatin, and S-1 for Unresectable Advanced Squamous Cell Carcinoma of the Esophagus.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2018 |
Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2019 |
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Diseas | 2019 |
Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Com | 2016 |
5 other studies available for tegafur and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Che | 2021 |
S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combination | 2019 |
S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
[A Case of Synchronous Esophageal and Gastric Cancer Successfully Treated Using Multimodal Therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2016 |
A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Cispla | 2017 |